Medical Detox Visits Doubled as Fentanyl Adulterants Shifted

When trying to withdraw from fentanyl safely, what is mixed into the supply now matters as much as the opioid itself. A study of two Philadelphia emergency departments found that visits for withdrawal treatment more than doubled as sedative adulterants changed.

Fewer people left with medication for opioid use disorder than before which makes a strong case for medical detox rather than trying to manage withdrawal at home.

Kory S. London and colleagues at Thomas Jefferson University led the research. The study appeared online July 8 2026 in Substance Use and Addiction Journal.

What The Study Looked At

Researchers reviewed every encounter that used a standardized opioid withdrawal order set at two Philadelphia hospitals from September 2022 through December 2025. One hospital served as an academic referral center, while the other operated as a community hospital.

The researchers divided the study period according to which alpha 2 agonist adulterant dominated the local fentanyl supply. Xylazine came first while medetomidine a more potent veterinary sedative largely displaced it later.

Withdrawal related chief complaints rose from 16.2% of these encounters to 42.7%. Primary diagnoses also shifted toward opioid withdrawal during that increase.

The treatment decline concerned the clinicians. Medication for opioid use disorder fell from 46.8% to 27.9% during the transition. Researchers reported an odds ratio of 2.27 with a p value below .001.

Why Adulterants Complicate Withdrawal

Alpha 2 adrenergic agonists such as xylazine and medetomidine are not opioids. They act on a separate receptor system so someone dependent on adulterated fentanyl can withdraw from two drug classes simultaneously.

Opioid medication addresses one of those drug classes. That helps explain why these cases can appear atypical with medical issues such as severe hypertension, rapid heart rate and vomiting occurring alongside ordinary opioid withdrawal.

The study authors also flagged another concern involving medications for opioid use disorder or MOUD. Starting buprenorphine before someone reaches an appropriate level of withdrawal can trigger precipitated withdrawal. This reaction can cause a sudden and severe escalation of symptoms.

What Drove People to Leave Before Treatment Finished

One finding challenges an obvious assumption about premature departure, which is that rates of leaving before treatment finished did not differ between the xylazine and medetomidine periods.

Instead operational factors predicted who left the earliest. Premature departure occurred more often at the academic center than the community hospital with 7.4% early departure compared with 3.3%. Researchers reported an adjusted odds ratio of 2.40 with a 95% confidence interval of 1.58 to 3.64.

Arrival time also mattered with evening and overnight arrivals showed higher rates of early departure with a p value of .006.

The practical takeaway is that how quickly a program assesses and doses someone in withdrawal can affect how long that person stays. Wait times therefore matter clinically rather than just as a service metric only.

Understanding Medication for Opioid Use Disorder

Buprenorphine and methadone are opioid agonist medications. They occupy the same receptors as fentanyl without producing the same cycle of intoxication and withdrawal.

Both medications have substantial evidence supporting their use for opioid use disorder. They also meaningfully reduce the risk of overdose death.

Naltrexone works differently because it blocks opioid receptors. Patients can only start it after they have fully withdrawn from opioids.

Detox alone does not constitute treatment. Tolerance falls quickly during withdrawal which sharply increases overdose risk afterward.

That makes leaving an emergency department without a medication plan a dangerous outcome. Continued medication and support can help mitigate that risk.

Finding Medical Detox

When you contact a detox program ask three specific questions. Find out whether the program can start buprenorphine or methadone during your stay and how quickly staff will assess you after arrival.

Ask whether the program can manage withdrawal complicated by sedative adulterants. These questions can help you identify a specific program equipped for the realities of today’s fentanyl supply.

The Detox.com directory lets you search medically supervised detox programs by location and level of care. You can also look for programs that offer medication assisted treatment on site. Call 800-996-6135Sponsored to communicate with a treatment specialist about your options.